

1 **Survival analysis of all critically ill patients with COVID-19 admitted to the**  
2 **main hospital in Mogadishu, Somalia, 30 March–12 June 2020: what**  
3 **interventions are proving effective?**  
4

5 Mohamed M. Ali<sup>1\*</sup> PhD, Sk Md Mamunur Rahman Malik<sup>2</sup> MD, Abdulrazaq Yusuf Ahmed<sup>3</sup>  
6 MSc, Ahmed Mohamed Bashir<sup>3,4</sup> MD, Abdulmunim Mohamed<sup>2</sup> MD, Abdulkadir Abdi<sup>2</sup> MD, and  
7 Majdouline Obtel<sup>2,5</sup> PhD.  
8  
9

10 **Affiliations**  
11

12 1- Department of Sexual and Reproductive Health and Research, World Health Organization,  
13 Geneva, Switzerland

14 2- World Health Organization Country Office, Mogadishu, Somalia

15 3- Demartino Hospital, Ministry of Health and Human Services, Federal Government of Somalia  
16 Mogadishu, Somalia

17 4- Somali Turkey RecepTeyyip Erdogan Training and Research Hospital, Mogadishu, Somalia

18 5- Laboratory of Community Health (Public Health, Preventive Medicine and Hygiene) &  
19 Laboratory of Biostatistics, Epidemiology and Clinical Research, Department of Public Health,  
20 Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco.  
21  
22

23 **Corresponding author**

24 Dr M M Ali, Research Leadership and Capacity buildings Department of Sexual and  
25 Reproductive Health and Research, World Health Organization, 20 Avenue Appia, 1211 Geneva  
26 27, Switzerland, Tel +41 22 791 3530, Email: [alim@who.int](mailto:alim@who.int).  
27  
28

29 **ABSTRACT**

30 **OBJECTIVES**

31 To determine risk factors for death in patients with COVID-19 admitted to the main public sector  
32 hospital in Somalia and identify interventions contributing to improved clinical outcome in a  
33 low-resource and fragile setting.

34 **SETTING**

35 Main public sector tertiary hospital in Mogadishu, Somalia.

36 **PARTICIPANTS**

37 All 131 laboratory-confirmed COVID-19 patients admitted to the main public tertiary hospital in  
38 Somalia between 30 March and 12 June 2020.

39 **MAIN OUTCOME MEASURES**

40 We extracted demographic and clinical data from hospital records of all 131 COVID-19 patients  
41 admitted to hospital until their death or recovery. We used Kaplan–Meier statistics to estimate  
42 survival probabilities and the log-rank test to assess significant differences in survival between  
43 groups. We used the Cox proportional hazard model to estimate likelihood of death and assess  
44 the effect of risk factors on survival.

45 **RESULTS**

46 Of the 131 patients, 52 (40%) died in the hospital and 79 (60%) survived to discharge. The  
47 factors independently associated with increased risk of in-hospital death were: age  $\geq$  60 years –  
48 survival probability on day 21 in patients  $<$  60 years was 0.789 (95% confidence interval (CI):  
49 0.658–0.874) compared with 0.339 (95% CI: 0.205–0.478) in patients  $\geq$  60 years; cardiovascular

50 disease (survival probability 0.478 (95% CI: 0.332–0.610) in patients with cardiovascular disease  
51 compared with 0.719 (95% CI: 0.601–0.807) in patients without cardiovascular disease); and  
52 non-invasive ventilation on admission – patients who were not ventilated were significantly more  
53 likely to survive than those who were ( $P < 0.001$ ).

#### 54 **CONCLUSION**

55 Our study, which includes the largest cohort of COVID-19 patients admitted to a single hospital  
56 in a sub-Saharan African country, confirms that underlying conditions and age are associated  
57 with increased risk of in-hospital death in patients with COVID-19. Our results show the  
58 advantage of medical oxygen over non-invasive ventilation in the treatment of patients with  
59 severe COVID-19 symptoms.

60

## 61 **Background**

62 On 16 March 2020, the Federal Ministry of Health and Human Services of Somalia reported the  
63 country's first laboratory-confirmed case of coronavirus disease-19 (COVID-19) in a Somali  
64 student arriving from China [1]. Since then and until 15 September 2020, the country has  
65 reported 3412 laboratory-confirmed cases of COVID-19, including 98 associated deaths out of  
66 24 320 samples tested [2]. Of these cases, 639 cases (19%) with COVID-19 were admitted to 19  
67 isolation centres designated by the government that were set up across the country. Of the cases  
68 hospitalized, only 242 patients presented with severe symptoms that needed critical care support  
69 in a tertiary-level hospital.

70 Given the fragility of the health care system in Somalia, it was anticipated that the system would  
71 be overwhelmed. The outbreak occurred at a time when the country had no intensive care beds,  
72 ventilators or a central supply of medical oxygen in the public sector. Ranked 193 out of 195  
73 countries on the Global Health Security Index [3,4], Somalia's health system has been weakened  
74 by decades of civil war, insecurity and disease outbreaks, as well as natural disasters such as  
75 droughts and floods. The current health workforce density in Somalia (0.34 health care workers  
76 per 1000 population) is substantially lower than the density needed for universal health coverage  
77 (UHC) – 4.45 health care workers per 1000 population by 2030 [5,6]. At the time the epidemic  
78 hit the country, there were only 15 intensive care unit beds (all in the private sector) for a  
79 population of more than 15 million. The disease surveillance system to detect, monitor and  
80 facilitate a rapid response to any outbreak is dysfunctional and fragmented.

81 To date, most of the laboratory-confirmed cases of COVID-19 in Somalia did not require  
82 hospitalization as over 80% were either asymptomatic or had mild symptoms (unpublished data  
83 from case-based surveillance, 2020). Between 16 March and 16 September 2020, out of 13 800

84 people who were tested in Mogadishu, 1531 (11%) were confirmed with COVID-19, 55 of  
85 whom died. Of these 1531 cases, only 131 with severe clinical disease were admitted to the main  
86 hospital of the country in Mogadishu.

87 Although data are available from developed and high-income countries on the clinical  
88 characteristics of COVID-19, and the outcome and risk factors for clinical outcome [5]8], few  
89 studies investigating the links between interventions and clinical outcome have been published  
90 from less developed countries [6].

91 Documenting the length of hospitalization and survival of patients with COVID-19 and the risk  
92 factors associated with death in low-resource settings could provide a better understanding of the  
93 impact of the disease and the usefulness of medical interventions as well as hospital capacity to  
94 cope with the surge in COVID-19 patients in such settings. This information can also guide  
95 policy responses on the use of low-cost, high-impact interventions in such setting to save lives  
96 and manage a surge in cases.

97 The main aim of this study was to assess the clinical characteristics of patients with COVID-19  
98 admitted to the main public-sector hospital in Somalia, estimate the length of hospital stay and  
99 identify the risk factors for death in these patients. The study also aimed to consider what  
100 interventions might help improve clinical outcomes in patients with severe COVID-19 in low-  
101 resource and fragile settings.

## 102 **Methods**

### 103 *Data extraction and outcomes*

104 We extracted information from clinical records on all 131 COVID19 patients admitted to De-  
105 Martino hospital, Mogadishu between 30 March 2020 and 12 June 2020. The information

106 extracted included: patient's place of residence, age, sex, date of admission, date of onset of  
107 symptoms, reported signs and symptoms (fever, shortness of breath, muscular pain, chest pain,  
108 abdominal pain, joint pain, general weakness, diarrhoea, cough, nausea or vomiting, sore throat,  
109 headache, runny nose, irritability and confusion), clinical characteristics (temperature,  
110 pharyngeal exudate, coma, abnormal lung X-ray, conjunctival infection, dyspnoea or  
111 tachypnoea, seizure and abnormal lung auscultation), comorbidities as reported by the patients  
112 (cardiovascular disease including hypertension, immunodeficiency including HIV, diabetes,  
113 renal disease and chronic lung disease), clinical interventions (delivery of oxygen (ventilation  
114 support through a facemask under positive pressure without the need for endotracheal intubation,  
115 non-invasive ventilation, inotropes and vasopressors, and antibiotics), and final outcome and date  
116 (survived or died). We transcribed individual patient data into an *Excel* file, and both the care  
117 providers and the information officers independently verified the data from the patient medical  
118 records for completeness and accuracy.

119 The primary outcome was survival status and time to outcome from date of hospitalization (in  
120 days).

### 121 *Statistical analysis*

122 We report the distribution of cases and deaths by sex and age group, and the distribution of  
123 symptoms, clinical characteristics, comorbidities and type of treatment by sex and age group. We  
124 used Kaplan–Meier statistics to estimate survival probabilities and the log-rank test to assess the  
125 significance of differences in survival between groups. We extended the survival analysis using  
126 the Cox proportional hazard model to estimate the likelihood of death and simultaneously assess  
127 the effect of several risk factors on survival, adjusting for confounding or effect modification.  
128 We also examined the assumption of proportionality.

129 We report numbers and percentages for binary variables, mean and median for continuous  
130 variables. We dichotomized age into  $< 60$  years and  $\geq 60$  years. We used Stata, version 16 for  
131 data quality assessment and analysis.  $P < 0.05$  was considered statistically significant.

## 132 **Patient and public involvement**

133 No patient involved

134

## 135 **Results**

136 We followed all 131 patients with COVID-19 admitted to the hospital until the end of their stay.  
137 The first admission was on 30 March 2020 and the last was on 12 June 2020. The final date of  
138 discharge or death was on 15 June 2020. The length of hospital stay ranged between 1 day and  
139 35 days with a median length of 5.5 days, interquartile range (IQR) 9 days.

140 Two thirds (89/131; 68%) of the patients were males, with mean age of 58.5 (SD: 16.1) years  
141 and median of 60 (IQR: 18) years) for males and 56.9 (SD: 17.1) years and median 55 (IQR: 27)  
142 years for females. Of the 131 patients, 52 (40%) died (Table 1).

143 Table 2 shows the distribution of patients according to signs and symptoms, clinical  
144 characteristics, comorbidities and the interventions given, by age group and sex. Most of the  
145 patients reported fever, shortness of breath and cough; few had abdominal pain, diarrhoea or a  
146 runny nose. Muscular and joint pain, general weakness and headache increased with age for both  
147 sexes. None of the patients presented with pharyngeal exudate, coma, conjunctival infection or  
148 seizures. However, 125/131 (95%) of patients had abnormal lung findings on X-ray and 124/131  
149 (95%) abnormal lung auscultation, and 119/131 (91%) presented with dyspnoea and/or

150 tachypnoea. More males had these clinical characteristics than females, but the frequency of the  
151 symptoms increased with age in females.

152 The main comorbidities were cardiovascular disease in 53/131 (40%) patients and diabetes in  
153 52/131 (40%). Cardiovascular disease was reported only by patients 40 years or older. Diabetes  
154 was more prevalent in females, 20/42 (48%), compared with in males, 32/89 (36%). Only two  
155 male patients had immunodeficiency. None of the female patients was pregnant or reported end  
156 of pregnancy in the 6 weeks before hospitalization. All the patients were given antibiotics, and  
157 oxygen therapy was given to 119/131 (91%) patients; the use of oxygen increased with patient  
158 age. Inotropes and vasopressors were given to 28/131 (21%) patients, all of whom were 40 years  
159 or older.

160 Table 3 shows the survival probabilities with 95% confidence intervals (CI) at days 7, 14 and 21  
161 after admission, by age group, sex, presence of cardiovascular disease and diabetes, and  
162 treatment with inotropes and vasopressors. Patients 60 years and older were significantly more  
163 likely to die than patients younger than 60 years ( $P < 0.003$ ), and the risk of death was  
164 significantly different between the two age groups at days 7, 14 and 21 (Figure 1a). The  
165 probability of surviving on day 21 in patients younger than 60 years was 0.789 (95% CI: 0.658–  
166 0.874) compared with 0.339 (95% CI: 0.205–0.478) in patients 60 years and older. The  
167 probability of death was very similar for males and females;  $P = 0.049$  (Figure 1a).

168

169 Patients without cardiovascular disease were significantly more likely to survive than those with  
170 cardiovascular disease ( $P = 0.0134$ ) (Figure 2). About half of the patients with cardiovascular  
171 disease survived the first week of hospitalization (survival probability = 0.478, 95% CI: 0.332–



172 0.610) compared with three-quarters of patients without cardiovascular disease (survival  
173 probability = 0.719, 95% CI: 0.601–0.807). However, the survival probabilities of patients  
174 without cardiovascular disease decreased by the third week and reached 0.558 (95% CI: 0.379–  
175 0.704) compared with 0.425 (95% CI: (0.265–0.576) Table 3). A similar pattern was seen in  
176 patients with diabetes, although the difference was smaller (Figure 2).

177  
178 Of 29 patients given inotropes or vasopressors, 25 (86%) died in the first week of admission. The  
179 survival probability of those who did not receive this intervention was significantly higher at day  
180 7 (survival probability = 0.769, 95% CI: 0.670–0.842), at day 14 (survival probability = 0.728,  
181 95% CI: 0.614–0.813) and at day 21 (survival probability = 0.655, 95% CI: 0.508–0.768) after  
182 admission compared with those who received the intervention (Table 3). Overall, patients not  
183 given inotropes or vasopressors were significantly more likely to survive than those given them  
184 ( $P < 0.001$ ) (Figure 3).

185  
186 Out of 131 patients, 12 were not given oxygen as their condition was considered mild and they  
187 all survived. We categorized the remaining 119 patients who were given oxygen on admission  
188 into three categories – not given non-invasive ventilation, delayed non-invasive ventilation and  
189 non-invasive ventilation given on admission – and calculated their survival probabilities  
190 (Figure 4 and Table 4). Those who were not ventilated or later ventilated had higher probability  
191 of survival than those who were ventilated on admission. Those who were ventilated on  
192 admission had a 22% chance of survival on day 3, compared with 83% on those who were not  
193 ventilated at all, and none of patients ventilated on admission survived after day 4 (Table 4). All

194 the patients who were given delayed ventilation, when their health condition worsened, also died  
195 and did not survive beyond day 16. Overall, patients who were not ventilated were significantly  
196 more likely to survive than those who were ventilated ( $P < 0.001$ ) (Figure 4).

197  
198 The likelihood of death for females and males by ventilation status was estimated using a Cox  
199 proportional hazard model, adjusting for age and two comorbidities. Table 5 shows the adjusted  
200 hazard ratios. The likelihood of death in female patients who were ventilated on admission  
201 (hazard ratio = 33.79, 95% CI: 4.09–279.07) was higher than in males who were ventilated on  
202 admission (hazard ratio = 8.65, 95% CI: 3.93–19.06).

## 203 **Discussion**

204 We assessed the demographic and clinical characteristics, outcomes and risk factors for death in  
205 all 131 patients with COVID-19 who were admitted to the De Martini hospital, the largest and  
206 only public sector hospital in Somalia, between 30 March and 12 June 2020. Before the COVID-  
207 19 outbreak, the hospital had no intensive care beds and it was not designed to care for severely  
208 ill patients. When COVID-19 began in the country, the government refurbished the De Martini  
209 hospital and fitted it with 20 intensive care beds. The decision was taken to transfer all severely  
210 ill patients diagnosed with COVID-19 to this hospital. However, there was no definitive criteria  
211 or strategy for discharging patients once admitted to the hospital.

212 Between 30 March and 12 June 2020, 79/131 patients (60%) were discharged alive and 52/131  
213 (40%) patients died. To our knowledge, this study includes the largest cohort of patients with  
214 COVID-19 admitted to a single hospital in a sub-Saharan African country.

215 The median length of hospital stay was 5.5 days (IQR: 9 days) with a range of 1–35 days and a  
216 mean of 7.7 days (SD: 6.9). In a similar study in Vietnam, the median length of hospital stay was  
217 21 (range: 16–34) days [6], while in the United States of America and several European  
218 countries, the length of stay was shorter with an average of 7–8 days only [10–12].

219 Two thirds (90/131; 69%) of the patients admitted in De Martini hospital during the study period  
220 were males, with mean age of 58.2 years for males and 56.9 years for females. These findings  
221 are consistent with other studies in Vietnam [6] and China [8] which suggest a slight gender  
222 difference in hospitalized patients with COVID-19. The signs and symptoms by age group and  
223 sex in our study do not differ from those reported in studies outside of Africa [8,9,14]; however  
224 there are no comparable data from African settings, especially in sub-Saharan African countries.

225 The main comorbidities found in the 131 patients with COVID-19 in our study are similar to the  
226 findings of other studies done in Africa [10] Although we are limited by the lack of population-  
227 based data on the prevalence of diabetes and cardiovascular diseases in males and females in  
228 Somalia, the fact that the proportion of female COVID-19 patients with diabetes in our study  
229 (48%; 20/42) was higher than males (32/89; 36%) is consistent with a study done in some areas  
230 of Somalia in 2016, which found that the prevalence of risk factors such as diabetes was higher  
231 in females than males, and CVD was higher among males, and in both sexes, the risk factors  
232 increased with age [15]. These findings are also consistent with another study that examined the  
233 burden of noncommunicable diseases in sub-Saharan Africa [12].

234 Our survival analysis and estimation of the hazard of death show that older age (> 60 years)  
235 significantly increased the likelihood of death due to COVID-19. However, patient's sex did not  
236 increase the likelihood of death. In a study in China, men were more than twice as likely to die  
237 from COVID-19 than women, which differs from our study and age > 50 years increased the risk

238 of death from COVID-19, which concurs with our study [13]. The use of vasopressors and  
239 inotropes did not reduce the risk of death, as patient received such treatment have very low  
240 probability of survival, and the adjusted hazard of death is 6.24 (95%CI: 3.55,10.99) compared  
241 to those who were not given the treatment (calculation not shown). Another study has reported  
242 similar results [8].

243 Similar to another study [18], we also found that the use of non-invasive ventilation was an  
244 indicator of severe disease and increased the risk of death. An important finding of our study is  
245 the comparative benefit in the clinical outcome of providing the patients with non-invasive  
246 ventilation and the use of medical oxygen. The survival probability of patients who were given  
247 medical oxygen only was higher (75%) at day 7, and consistently remained at over 70% even at  
248 day 14 after admission, than in patients treated with both oxygen and non-invasive ventilation  
249 (10%), the risk of death for patients given non-invasive ventilation with medical oxygen was  
250 5.43 times higher than in patients given only oxygen (calculation not shown). The lack of clinical  
251 benefit from the use of ventilation has also been reported in other settings [11,19,[16].

252

253 As the COVID-19 pandemic spread around the world, there was concern that the infection would  
254 have a substantial impact on African countries because they were unprepared to deal with such a  
255 crisis [17][18]. While this is true, the level of preparedness was judged by the number and  
256 availability of intensive care beds and ventilators per million of people's use. However,  
257 ventilators, although useful for patients suffering from severe symptoms, are not a feasible  
258 treatment in countries where skilled and trained staff, such as specialized nurses and intensivists  
259 to manage intensive care units and ventilators, are not available, as was the case in our hospital.

260 Our study has a number of limitations. First, the dataset does not include all clinical variables  
261 related to the evolution of COVID-19, and data were collected manually, although the data were  
262 checked by two people to minimize error. Nonetheless, human error and missing information  
263 should be taken into consideration while analysing and interpreting the data. Second, our data  
264 include information on deaths from laboratory-confirmed cases and do not include other patients  
265 who could not be tested. This may lead to underestimation of our findings (of the benefit of  
266 oxygen over non-invasive ventilation) and limit their generalizability.

267 Despite these limitations, our study contributes to an understanding of the risk factors for death  
268 from COVID-19 in Somalia. Risk factors for death from COVID-19 have not been studied or  
269 published from sub-Saharan countries before.

## 270 **Conclusion**

271 To our knowledge, this is the first evidence from a fragile and resource-poor setting on the  
272 advantage of medical oxygen over non-invasive ventilation in the treatment and care of patients  
273 with severe symptoms of COVID-19. Information on the usefulness of medical oxygen is  
274 reported from the United States [15] and Italy [16], but there has been no such evidence from any  
275 African country so far. The study has important policy implications by highlighting the value of  
276 available, accessible and affordable low-cost interventions in a fragile and resource-poor setting.

277 As reported in most sub-Saharan African countries [19], medical oxygen in secondary and  
278 tertiary health care settings is not always available even though it is well established that this  
279 therapy is fundamental for the treatment of severely ill patients, especially for pneumonia, which  
280 is a leading cause of death in elderly people and children under 5 years. Its usefulness in the

281 treatment of patients with COVID-19 is further evidence of the urgent need to ensure that  
282 medical oxygen is always available in these settings.

283

#### 284 **Acknowledgement**

285 We would like to acknowledge Jonathan Aaron Polonsky for his review and Ms Fiona Curlet for  
286 her review and editing

#### 287 **Funding**

288 This research received no specific grant from any funding agency in the public, commercial or  
289 not-for-profit sectors

#### 290 **Competing interests:**

291 None.

#### 292 **Patient consent for publication**

293 Not required.

294

295

## 296 **References**

- 297 1. COVID-19 situation Report-21. Cairo: World Health Organization, Regional Office for the  
298 Eastern Mediterranean. Available at:  
299 [http://www.emro.who.int/images/stories/coronavirus/documents/covid-](http://www.emro.who.int/images/stories/coronavirus/documents/covid-19_sitrep_21.pdf?ua=1)  
300 [19\\_sitrep\\_21.pdf?ua=1](http://www.emro.who.int/images/stories/coronavirus/documents/covid-19_sitrep_21.pdf?ua=1) (accessed 10 October, 2020).
- 301 2. COVID-19 dashboard, Somalia [internet]. Mogadishu: Ministry of Health Federal Republic  
302 of Somalia. Available at: <https://moh.gov.so/en/covid19/> (accessed 7 August, 2020).
- 303 3. Aitken T, Lee Chin K, Liew D, Ofori-Asenso R. Rethinking pandemic preparation: Global  
304 Health Security Index (GHSI) is predictive of COVID-19 burden, but in the opposite  
305 direction. *J Infect.* 2020;81(2):318–56. doi:10.1016/j.jinf.2020.04.017
- 306 4. GHS Index [website]. Available at: <https://www.ghsindex.org/> (accessed 7 August, 2020).
- 307 5. Somalia. Health profile. Cairo: World Health Organization, Regional Office for the Eastern  
308 Mediterranean; 2017. Available at: [https://rho.emro.who.int/sites/default/files/Profiles-](https://rho.emro.who.int/sites/default/files/Profiles-briefs-files/EMROPUB_EN_19617-SOM.pdf)  
309 [briefs-files/EMROPUB\\_EN\\_19617-SOM.pdf](https://rho.emro.who.int/sites/default/files/Profiles-briefs-files/EMROPUB_EN_19617-SOM.pdf) (accessed 18 October 2020).
- 310 6. Health workforce requirements for universal health coverage and the Sustainable  
311 Development Goals. Geneva: World Health Organization; 2016. Available at:  
312 [https://apps.who.int/iris/bitstream/handle/10665/250330/9789241511407-](https://apps.who.int/iris/bitstream/handle/10665/250330/9789241511407-eng.pdf;sequence=1)  
313 [eng.pdf;sequence=1](https://apps.who.int/iris/bitstream/handle/10665/250330/9789241511407-eng.pdf;sequence=1) (accessed 18 October 2020).
- 314 7. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill  
315 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,  
316 observational study. *Lancet Respir Med.* 2020;8(5):475–81. doi:10.1016/S2213-  
317 2600(20)30079-5

- 318 8. Salinas-Escudero G, Carrillo-Vega MF, Granados-García V, Martínez-Valverde S,  
319 Toledano-Toledano F, Garduño-Espinosa J. A survival analysis of COVID-19 in the  
320 Mexican population 2020 (preprint). Research square; 2020. doi:10.21203/rs.3.rs-39083/v1
- 321 9. Thai PQ, Toan DTT, Dinh TS, Hoang TH Van, Luu NM, Xuan Hung L, et al. Factors  
322 associated with the duration of hospitalization among COVID-19 patients in Vietnam: a  
323 survival analysis. *Epidemiol Infect.* 2020;145:e114. doi:10.1017/S0950268820001259
- 324 10. Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, et al. Severe outcomes among  
325 patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16,  
326 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(12):343–6. doi:10.15585/mmwr.mm6912e2
- 327 11. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in  
328 critically ill patients in the Seattle region—case series. *N Engl J Med.* 2020;382(21):2012–  
329 22. doi:10.1056/NEJMoa2004500
- 330 12. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of  
331 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical  
332 Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:1–12.  
333 doi:10.1136/bmj.m1985
- 334 13. Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease  
335 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese  
336 Center for Disease Control and Prevention. *JAMA.* 2020;323(13):1239–42.  
337 doi:10.1001/jama.2020.2648
- 338 14. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute  
339 respiratory distress syndrome and death in patients with coronavirus disease 2019



- 340 pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934–43.  
341 doi:10.1001/jamainternmed.2020.0994
- 342 15. Ahmed SH, Meyer HE, Kjøllesdal MK, Marjerrison N, Mdala I, Htet AS, et al. The  
343 prevalence of selected risk factors for non-communicable diseases in Hargeisa, Somaliland:  
344 a cross-sectional study. *BMC Public Health.* 2019;19(1):878. doi:10.1186/s12889-019-7101-  
345 x
- 346 16. Dalal S, Beunza JJ, Volmink J, Adebamowo C, Bajunirwe F, Njelekela M, et al. Non-  
347 communicable diseases in sub-Saharan Africa: what we know now. *Int J Epidemiol.*  
348 2011;40(4):885–901. doi:10.1093/ije/dyr050
- 349 17. Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical characteristics and  
350 prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168  
351 severe patients. *PLoS Pathog.* 2020;16(4):e1008520. doi:10.1371/journal.ppat.1008520
- 352 18. Zareifopoulos N, Lagadinou M, Karela A, Platanaki C, Karantzogiannis G, Velissaris D.  
353 Management of COVID-19: the risks associated with treatment are clear, but the benefits  
354 remain uncertain. *Monaldi Arch Chest Dis.* 2020;90(2). doi:10.4081/monaldi.2020.1342
- 355 19. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.  
356 Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized  
357 with COVID-19 in the New York City area. *JAMA.* 2020;323(20):2052–9.  
358 doi:10.1001/jama.2020.6775
- 359 20. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline  
360 characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs  
361 of the Lombardy Region, Italy. *JAMA.* 2020;323(16):1574–81. doi:10.1001/jama.2020.5394

- 362 21. Nkengasong JN, Mankoula W. Looming threat of COVID-19 infection in Africa: act  
363 collectively, and fast. *Lancet*. 2020;395(10227):841–2. doi:10.1016/S0140-6736(20)30464-5
- 364 22. El-Sadr WM, Justman J. Africa in the path of Covid-19. *N Engl J Med*. 2020;383(3):e11.  
365 doi:10.1056/NEJMp2008193
- 366 23. Mangipudi S, Leather A, Seedat A, Davies J. Oxygen availability in sub-Saharan African  
367 countries: a call for data to inform service delivery. *Lancet Glob Health*. 2020;8(9):e1123–  
368 e1124. doi:10.1016/S2214-109X(20)30298-9
- 369

370 **Table 1: Number of patients with COVID-19 and deaths associated with COVID-19, by**  
371 **age and sex, Somalia, 2020.**

Age group (years)	Males		Females	
	Total no. of patients	No. died	Total no. of patients	No. died
10–19	2	0	0	0
20–29	3	0	4	2
30–39	9	0	6	0
40–49	5	2	4	0
50–59	15	4	11	4
60–69	32	19	9	4
70–79	17	8	3	1
80+	6	5	5	3
<b>Total</b>	<b>89</b>	<b>38</b>	<b>42</b>	<b>14</b>

372

373

374

375 **Table 2: Distribution of the patients according to disease characteristics and treatment, by**  
 376 **sex and age group, Somalia, 2020.**

Variable	Females (no.)			Males (no.)		
	Age (years)			Age (years)		
	< 40	40–59	≥ 60	< 40	40–59	≥ 60
<b>Symptoms and signs</b>						
Fever	9	13	17	13	19	54
Shortness of breath	8	15	16	14	20	52
Muscular pain	1	1	6	1	2	11
Chest pain	3	4	9	4	11	21
Abdominal pain	2	2	2	0	1	5
Joint pain	1	1	9	2	3	18
General weakness	3	4	10	3	6	24
Diarrhoea	1	1	1	0	2	5
Cough	9	15	16	14	19	52
Nausea/Vomiting	2	3	0	0	1	6
Sore throat	4	6	8	5	9	26
Headache	4	5	12	7	12	30
Runny nose	0	0	0	0	0	4
Irritability confusion	2	1	6	1	6	15
<b>Clinical characteristics</b>						
Abnormal lung X-ray findings	7	13	17	14	20	54
Dyspnea tachypnea	8	14	17	14	19	47
Abnormal lung auscultation	7	14	17	14	20	52
<b>Comorbidities</b>						
Cardiovascular disease	0	6	8	0	10	29
Immunodeficiency, including HIV	0	0	0	1	0	1
Diabetes	1	9	10	2	9	21
Renal disease	1	1	1	0	1	2
Chronic lung disease	1	1	2	0	1	10
<b>Treatment</b>						
Oxygen therapy	7	14	17	11	17	53
Non-invasive ventilation	1	1	5	0	3	20
Inotropes and vasopressors	0	1	3	0	4	20
Antibiotics	10	15	17	14	20	55
<b>Total</b>	<b>10</b>	<b>15</b>	<b>17</b>	<b>14</b>	<b>20</b>	<b>55</b>

377

378

379 **Table 3: Survival probability according to patient characteristics and treatment on day 7,**  
 380 **14 and 21 after admission to hospital, Somalia, 2020.**

Variable	At day 7	At day 14	At day 21
	Survival probability (95% CI)	Survival probability (95% CI)	Survival probability (95% CI)
<b>Age group (years)</b>			
< 60	<b>0.789 (0.658–0.874)</b>	<b>0.789 (0.658–0.874)</b>	<b>0.789 (0.658–0.874)</b>
≥ 60	<b>0.489 (0.365–0.602)</b>	<b>0.440 (0.312–0.561)</b>	<b>0.339 (0.205–0.478)</b>
<b>Sex</b>			
Female	0.669 (0.497–0.794)	0.669 (0.497–0.794)	0.535 (0.254–0.752)
Male	0.600 (0.487–0.696)	0.557 (0.436–0.662)	0.488 (0.348–0.613)
<b>Cardiovascular disease</b>			
No	0.719 (0.601–0.807)	0.697 (0.574–0.790)	0.558 (0.379–0.704)
Yes	0.478 (0.332–0.610)	0.425 (0.265–0.576)	0.425 (0.265–0.576)
<b>Diabetes</b>			
No	0.704 (0.585–0.795)	0.684 (0.561–0.779)	0.547 (0.372–0.693)
Yes	0.499 (0.353–0.629)	0.449 (0.290–0.596)	0.449 (0.290–0.596)
<b>Inotropes or vasopressors</b>			
No	<b>0.769 (0.670–0.842)</b>	<b>0.728 (0.614–0.813)</b>	<b>0.655 (0.508–0.768)</b>
Yes	<b>0.107 (0.027–0.251)</b>	<b>0.107 (0.027–0.251)</b>	<b>0.000 (0.000–0.000)</b>

381

382 CI: confidence interval.

383

384 **Table 4: Survival probability according to length of time after admission, by**  
385 **administration of non-invasive ventilation, Somalia, 2020.**

Length of time after admission (days)	No ventilation	Delayed ventilation	Ventilation on admission
	Survival probability (95% CI)	Survival probability (95% CI)	Survival probability (95% CI)
1	0.966 (0.899–0.989)	1.000 (1.000–1.000)	0.739 (0.509–0.873)
2	0.910 (0.827–0.954)	1.000 (1.000–1.000)	0.304 (0.135–0.493)
3	0.828 (0.731–0.893)	1.000 (1.000–1.000)	0.217 (0.079–0.399)
4	0.778 (0.675–0.853)	1.000 (1.000–1.000)	0.087 (0.015–0.242)
5	0.753 (0.647–0.832)	0.714 (0.258–0.920)	
7	0.753 (0.647–0.832)	0.571 (0.172–0.837)	
9	0.737 (0.627–0.819)	0.571 (0.172–0.837)	
14	0.737 (0.627–0.819)	0.429 (0.098–0.734)	
15	0.737 (0.627–0.819)	0.214 (0.012–0.586)	
16	0.698 (0.564–0.798)	0.214 (0.012–0.586)	
21	0.698 (0.564–0.798)		

386 CI: confidence interval

387


388 **Table 5: Adjusted hazard ratios for death in hospitalized patients with COVID-19, by sex,**  
389 **Somalia, 2020.**

Variable	Adjusted hazard ratios (95% CI)	
	Females	Males
<b>Age (years)</b>		
< 60	1.00	
≥ 60	1.08 (0.34–3.40)	1.84 (0.74–4.57)
<b>Cardiovascular disease</b>		
No	1.00	1.00
Yes	0.72 (0.16–3.28)	1.67 (0.86–3.26)
<b>Diabetes</b>		
No	1.00	1.00
Yes	2.14 (0.65–7.08)	1.33 (0.69–2.56)
<b>Non-invasive ventilation</b>		
No	1.00	1.00
Delayed	2.20 (0.42–11.40)	2.26 (0.71–7.18)
On admission	<b>33.79 (4.09–279.07)</b>	<b>8.65 (3.93–19.06)</b>

390

Figure 1: Kaplan–Meier survival estimates by age and sex

Age group



Sex






Figure 2: Kaplan–Meier survival estimates by comorbidity





Figure 3: Kaplan–Meier survival estimates by use of inotropes and vasopressors




Figure 4: Kaplan–Meier survival estimates by ventilation use

